Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Auditor change
Viridian Therapeutics, Inc. (MGEN) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
07/24/2023 S-3ASR Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers:
07/17/2023 8-K Quarterly results
07/10/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease",
"Viridian Therapeutics, Inc. Data Presentation, dated July 2023"
06/16/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Viridian Therapeutics, Inc. Amended and Restated 2016 Equity Incentive Plan",
"Viridian Therapeutics, Inc. Amended and Restated 2016 Equity Incentive Plan"
06/02/2023 144 Form 144 - Report of proposed sale of securities:
05/11/2023 SC 13G Paradigm Biocapital Advisors LP reports a 5.4% stake in Viridian Therapeutics, Inc.
05/10/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "Viridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update"
04/28/2023 ARS Form ARS - Annual Report to Security Holders:
04/28/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/28/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/10/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
03/09/2023 10-K Annual Report for the period ended December 31, 2022
03/08/2023 8-K Quarterly results
Docs: "Viridian Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates"
02/14/2023 SC 13G/A Paradigm Biocapital Advisors LP reports a 4.7% stake in Viridian Therapeutics Inc.
02/14/2023 SC 13G/A Cormorant Asset Management, LP reports a 2.7% stake in Viridian Therapeutics, Inc.
02/14/2023 SC 13G/A TCG Crossover GP I, LLC reports a 2.4% stake in Viridian Therapeutics, Inc.
02/14/2023 SC 13G/A BIOTECHNOLOGY VALUE FUND L P reports a 5.6% stake in Viridian Therapeutics, Inc.
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2023 SC 13G VANGUARD GROUP INC reports a 5.2% stake in Viridian Therapeutics Inc.
02/06/2023 8-K Quarterly results
02/03/2023 SC 13G BlackRock Inc. reports a 6.9% stake in MIRAGEN THERAPEUTICS, INC.
01/26/2023 SC 13G/A MILLENNIUM MANAGEMENT LLC reports a 2% stake in VIRIDIAN THERAPEUTICS, INC.
01/09/2023 8-K Investor presentation
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease",
"Viridian Therapeutics, Inc. Topline Data Presentation, dated January 2023"
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
09/09/2022 S-3ASR Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers:
08/19/2022 SC 13D/A Fairmount Funds Management LLC reports a 20% stake in Viridian Therapeutics, Inc.
08/19/2022 8-K Quarterly results
08/18/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/16/2022 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
08/16/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy